Icosabutate, A Novel Structurally Engineered Fatty Acid, Significantly Reduces Relevant Markers Of Nash And Fibrosis In 16 Weeks: Interim Analysis Results Of The Icona Trial
JOURNAL OF HEPATOLOGY(2021)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要